BioGaia AB (publ)

Stockholm Stock Exchange BIOG-B.ST

BioGaia AB (publ) Cash and Short-Term Investments for the year ending December 31, 2023: USD 152.41 M

BioGaia AB (publ) Cash and Short-Term Investments is USD 152.41 M for the year ending December 31, 2023, a 7.23% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

BioGaia AB (publ) Cash and Short-Term Investments for the year ending December 31, 2022 was USD 142.14 M, a -13.05% change year over year.
BioGaia AB (publ) Cash and Short-Term Investments for the year ending December 31, 2021 was USD 163.46 M, a -8.12% change year over year.
BioGaia AB (publ) Cash and Short-Term Investments for the year ending December 31, 2020 was USD 177.91 M, a 664.15% change year over year.
BioGaia AB (publ) Cash and Short-Term Investments for the year ending December 31, 2019 was USD 23.28 M, a -28.59% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

Stockholm Stock Exchange: BIOG-B.ST

BioGaia AB (publ)

CEO	Ms. Theresa P. Agnew
IPO Date	Jan. 3, 2000
Location	Sweden
Headquarters	Kungsbroplan 3
Employees	222
Sector	Consumers Staples
Industries Dairy & Milk Baby & Childcare Biotechnology Frozen Foods Non-Alcoholic Beverages Personal Care Pharmaceuticals Plastics

Description

BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates through three segments: Pediatrics, Adult Health, and Other. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of infantile colic and digestive health in children; antibiotic-associated and acute diarrhoea; gingivitis; periodontal disease; general health; Helicobacter pylorithe gastric ulcer bacterium; and low bone density. It offers its products under the BioGaia brand name. BioGaia AB (publ) was founded in 1990 and is headquartered in Stockholm, Sweden.

Key trends

Past 5 years